Management of Elevated INR in Patients with Artificial Heart Valves

Introduction to INR Management

The American College of Cardiology recommends a target INR of 2.5-3.5 for most mechanical valves, with a small dose reduction of 5-10% of the weekly dose and recheck of INR in 3-5 days for patients with an INR of 3.41 1, 2

Bleeding risk increases significantly when INR rises above 3.0-3.5, and the risk becomes exponentially higher as INR continues to climb, according to the Journal of the American College of Cardiology 3
The American Geriatrics Society notes that elderly patients exhibit greater PT/INR response to warfarin and have increased risk of intracranial bleeding, particularly when INR exceeds 3.5 1

Reduce the total weekly warfarin dose by 5-10% rather than withholding doses, as this patient is not severely overanticoagulated, recommends the American College of Cardiology 1
Do not withhold warfarin doses or give vitamin K, as the INR is below 5.0 and the patient has no bleeding symptoms, according to the American College of Cardiology 1, 2

Recheck INR in 3-5 days after the dose adjustment to ensure the patient returns to therapeutic range without dropping too low, recommends the American College of Cardiology 1, 2

Investigate potential causes for the INR increase before making dose changes, such as recent medication additions, dietary changes, acute illness, or adherence issues, according to the Journal of the American College of Cardiology and the American College of Cardiology 1, 2, 3
Assess for any signs of bleeding, including bruising, epistaxis, hematuria, or gastrointestinal bleeding, though management remains the same at this INR level unless active bleeding is present, recommends the American College of Cardiology 1